Antibiofilm activity of GlmU enzyme inhibitors against catheter-associated uropathogens.

Antimicrobial Agents and Chemotherapy
Euan BurtonSrinivasa Madhyastha

Abstract

The colonization of uropathogenic bacteria on urinary catheters resulting in biofilm formation frequently leads to the infection of surrounding tissue and often requires removal of the catheter. Infections associated with biofilms are difficult to treat since they may be more than 1,000 times more resistant to antibiotics than their planktonic counterparts. We have developed an antibiofilm composition comprising an N-acetyl-D-glucosamine-1-phosphate acetyltransferase (GlmU) inhibitor and protamine sulfate, a cationic polypeptide. The antibiofilm activity of GlmU inhibitors, such as iodoacetamide (IDA), N-ethyl maleimide (NEM), and NEM analogs, including N-phenyl maleimide, N,N'-(1,2-phenylene)dimaleimide (oPDM), and N-(1-pyrenyl)maleimide (PyrM), was tested against that of catheter-associated uropathogens. Both IDA and NEM inhibited biofilm formation in Escherichia coli. All NEM analogs showed antibiofilm activity against clinical isolates of E. coli, Pseudomonas aeruginosa, Klebsiella pneumoniae, Staphylococcus epidermidis, and Enterococcus faecalis. The combination of oPDM with protamine sulfate (PS) enhanced its antibiofilm activity and reduced its effective concentration to as low as 12.5 microM. In addition, we found that ...Continue Reading

References

May 1, 1982·The Journal of Infectious Diseases·M S GreenP Amit
Sep 1, 1993·Antimicrobial Agents and Chemotherapy·J R JohnsonA J Conway
Mar 1, 1997·Letters in Applied Microbiology·T Brooks, C W Keevil
Jan 8, 1999·The New England Journal of Medicine·R O DarouicheG Mayhall
May 21, 1999·Science·J W CostertonE P Greenberg
Apr 11, 2001·Emerging Infectious Diseases·R M Donlan
Apr 17, 2001·Antimicrobial Agents and Chemotherapy·P DomenicoB A Cunha
Jun 13, 2002·Il Farmaco·Frederic ZentzDanielle Sirot
Jul 27, 2002·Annual Review of Microbiology·P StoodleyJ W Costerton
Feb 4, 2003·Nature Reviews. Drug Discovery·David Davies
Nov 26, 2004·The Journal of Antimicrobial Chemotherapy·E PresterlW Graninger
Jan 11, 2005·Trends in Microbiology·C A FuxP Stoodley
Feb 15, 2011·Infectious Disease Clinics of North America·Carol E Chenoweth, Sanjay Saint

❮ Previous
Next ❯

Citations

Oct 24, 2008·Current Infectious Disease Reports·Paola Lichtenberger, Thomas M Hooton
Apr 18, 2012·Nature Reviews. Urology·Danish M Siddiq, Rabih O Darouiche
Apr 5, 2011·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Rodney M Donlan
Feb 25, 2009·Acta Crystallographica. Section D, Biological Crystallography·Zhening ZhangChristopher J Squire
Dec 10, 2008·Antimicrobial Agents and Chemotherapy·George V TetzVictor V Tetz
Dec 22, 2010·Antimicrobial Agents and Chemotherapy·Mei-Hui LinShih-Tung Liu
Apr 8, 2009·Antimicrobial Agents and Chemotherapy·Mark P PereiraEric D Brown
Sep 26, 2012·Antimicrobial Agents and Chemotherapy·Michael L VasilArthur E Pritchard
Jan 19, 2008·Clinical Microbiology Reviews·S M JacobsenM E Shirtliff
Sep 1, 2011·Indian Journal of Medical Sciences·Ethel SumanM Shashidhar Kotian
May 15, 2013·Journal of Enzyme Inhibition and Medicinal Chemistry·Rajesh A RaneNishant K Shah
Nov 26, 2010·Critical Reviews in Biotechnology·Ankur GautamRupinder Tewari
Dec 23, 2015·European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences·Chitra Rani, Inshad Ali Khan
Oct 4, 2015·International Journal of Biological Macromolecules·P S Rajesh, V Ravishankar Rai
Mar 18, 2008·Journal of Controlled Release : Official Journal of the Controlled Release Society·Shunmugaperumal TamilvananAnnick Ludwig
Dec 24, 2011·Annals of the New York Academy of Sciences·Megan R Kiedrowski, Alexander R Horswill
Feb 13, 2008·FEMS Microbiology Reviews·Hélène BarreteauDidier Blanot
May 13, 2015·Biomaterials·David SchwartzmanPhil G Campbell
Nov 25, 2014·Archives of Microbiology·Delphine PatinDidier Blanot
Feb 7, 2018·Nanomaterials·Frans Ricardo TamaraYi-Cheng Ho
Jun 11, 2014·Acta Crystallographica. Section F, Structural Biology Communications·Neha VithaniBalaji Prakash
Sep 11, 2019·Journal of Applied Microbiology·M AyyashA G Al-Bakri
Oct 17, 2019·Journal of Applied Microbiology·Z YanB V Kjellerup
Mar 16, 2007·Expert Review of Medical Devices·Turlough M HamillSean P Gorman
Aug 22, 2017·Frontiers in Cellular and Infection Microbiology·Cheepurupalli LalithaJayapradha Ramakrishnan
Nov 14, 2020·Carbohydrate Polymers·Durairajan RubiniParamasivam Nithyanand

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antifungals (ASM)

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.

Biofilm & Infectious Disease

Biofilm formation is a key virulence factor for a wide range of microorganisms that cause chronic infections.Here is the latest research on biofilm and infectious diseases.

Biofilms

Biofilms are adherent bacterial communities embedded in a polymer matrix and can cause persistent human infections that are highly resistant to antibiotics. Discover the latest research on Biofilms here.

CRISPR Screens in Drug Resistance

CRISPR-Cas system enables the editing of genes to create or correct mutations. This feed focuses on the application of CRISPR-Cas system in high-throughput genome-wide screens to identify genes that may confer drug resistance.

Antifungals

An antifungal, also known as an antimycotic medication, is a pharmaceutical fungicide or fungistatic used to treat and prevent mycosis such as athlete's foot, ringworm, candidiasis, cryptococcal meningitis, and others. Discover the latest research on antifungals here.